Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
154 stopped studies mapped to Follicular Lymphoma and descendants · 86% state a reason
Over the 154 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Phase 2 | terminated | Jul 12, 2022 | University of Washington | The trial closed early due to slow accrual. | Enrollment / accrual |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least… | — | withdrawn | Dec 15, 2025 | Ipsen | Withdrawn prior to enrolment after review of updated safety data | Safety / toxicity |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | terminated | Nov 16, 2022 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in… | Phase 3 | withdrawn | Mar 15, 2024 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Replaced with another clinical trial. | Other (stated, no rule matched) |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT03919175 | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and… | Phase 2 | terminated | Apr 18, 2019 | Massachusetts General Hospital | Umbralisib development terminated; closed to accrual 8/29/2022 | Enrollment / accrual |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With…(Mandolin) | Phase 2 | withdrawn | Oct 5, 2023 | Epizyme, Inc. | Never started | Other (stated, no rule matched) |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa… | Phase 2 | suspended | Aug 28, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT03498612 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Phase 2 | terminated | Apr 13, 2018 | University of Washington | Closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or… | Phase 2 | terminated | Jan 17, 2018 | University of Washington | Study terminated to end of funding. | Funding |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | Phase 1 | terminated | Feb 3, 2021 | Adicet Therapeutics | Terminated - Halted Prematurely | Other (stated, no rule matched) |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial… | Early Phase 1 | terminated | Nov 17, 2016 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT06290622 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Phase 1 | withdrawn | Mar 4, 2024 | University of Alabama at Birmingham | Investigator request to no longer pursue this study. Lack of support from drug company. This trial… | Investigator |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | — | terminated | Jul 29, 2021 | Celgene | Slow accrual | Enrollment / accrual |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | Phase 1 | terminated | Aug 17, 2018 | Dana-Farber Cancer Institute | Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients… | Drug supply |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory… | Phase 2 | terminated | Apr 10, 2015 | Janssen Research & Development, LLC | DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort… | Efficacy / futility |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab… | Phase 1 | withdrawn | Apr 19, 2016 | Janssen Research & Development, LLC | not stated | Not stated |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R… | Phase 2 | terminated | Mar 12, 2020 | Zhejiang DTRM Biopharma | Despite the efforts of our dedicated team and initial progress, we were unable to secure the… | Funding |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After… | Phase 2 | terminated | Dec 7, 2018 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | Phase 2 | terminated | Mar 26, 2019 | Fondazione Italiana Linfomi - ETS | Study was halted prematurely due to safety, since tocity stopping rules have been met | Safety / toxicity |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL… | Phase 3 | terminated | Feb 9, 2021 | MEI Pharma, Inc. | Discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment… | Phase 2 | terminated | Dec 9, 2020 | Academic and Community Cancer Research United | Trial closed due to low accrual rate | Enrollment / accrual |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Sep 10, 2019 | IGM Biosciences, Inc. | Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases… | Sponsor / business decision |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | Phase 1 / Phase 2 | terminated | Nov 20, 2014 | AHS Cancer Control Alberta | It did not show a significant benefit to justify completing the full target accrual. | Enrollment / accrual |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular… | Phase 1 / Phase 2 | terminated | Jan 25, 2021 | University of Chicago | funding | Funding |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Aug 9, 2021 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects… | Phase 2 | terminated | Feb 21, 2021 | Epizyme, Inc. | Decision to terminate EZH-1401 was solely due to company business decision. | Sponsor / business decision |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in… | Phase 1 | terminated | Jun 28, 2018 | Amgen | Amgen decided to discontinue study because of a business decision and not because of safety reasons | Safety / toxicity |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | Phase 2 | terminated | May 21, 2015 | Swiss Cancer Institute | The premature termination is based on the decision by the SAKK board on November 14, 2020 due to… | Funding |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell… | Phase 1 / Phase 2 | terminated | Nov 10, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in…(LOTIS-6) | Phase 2 | terminated | Jan 7, 2021 | ADC Therapeutics S.A. | Administrative decision (not due to safety reason) | Safety / toxicity |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 1 | withdrawn | May 19, 2023 | Innovent Biologics (Suzhou) Co. Ltd. | Development strategy adjustment | Sponsor / business decision |
| NCT02204982 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously…(DYNAMO + R) | Phase 3 | terminated | Jul 31, 2014 | SecuraBio | Sponsor is focusing on studies which can enable registration of duvelisib | Other (stated, no rule matched) |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With… | Phase 1 / Phase 2 | terminated | Mar 18, 2015 | SecuraBio | Sponsor is focusing on studies which can enable registration of duvelisib. | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | Phase 3 | terminated | Aug 31, 2015 | Gilead Sciences | Gilead has made the decision to close the study due to enrollment challenges | Enrollment / accrual |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Vaccine manufacturing has been suspended | Drug supply |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve… | Phase 2 | terminated | Feb 4, 2019 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials